Here are five takeaways from the company’s preliminary report:
1. Revenue is expected to be $41.5 million to $42 million, which would be a 17 to 18 percent increase in sales per day compared to the same time last year.
2. Revenue from U.S. spinal implants is expected to reflect a 28 to 29 percent increase in sales per day from the same time last year.
3. Revenue from U.S. orthobiologics is expected to reflect an 11 to 12 percent increase in sales per day from the same time last year.
4. Cash, cash equivalents and investments were expected to be $88 million at March 31.
5. SeaSpine expects full-year 2021 revenue to reach $200 million to $205 million after its planned acquisition of 7D Surgical in the second quarter.
More articles on devices:
Which spine procedures are surgeons migrating to the ASC in 2021?
The next 3 years in spine: What will gain ground on fusion?
5 ways spine surgery is changing: ASCs, endoscopic surgery & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.